Alembic Pharmaceuticals enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


15,623	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
196	196	83.5	120	75.5
−5.8	−5.8	−1.4	0.0	0.0
1,361	1,361	1,196	430	636
16,781	—	—	—	—
1,164	1,164	1,112	310	560
₹853.80	—	—	—	—

7,030	7,030	6,385	5,249	5,006
19.4%	19.4%	18.7%	8.2%	12.7%
0.08×	—	—	—	—

2.16×	—	—	—	—
14.36×	—	—	—	—
20.30×	—	—	—	—
48.21×	—	—	—	—
7,784	7,345	6,672	6,229	5,653
1,169	1,118	1,008	933	708
826	800	730	661	433
—	783	88.0	803	724
348	348	−476	476	281
—	345	−490	474	279
—	435	564	327	443

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,623 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	15,622.8
- Cash, Equiv & ST Investments	75.5	120.2	83.5	196.4	196.4
+ Minority Interest	0.0	0.0	-1.4	-5.8	-5.8
+ Total Debt	635.9	430.5	1,195.6	1,360.9	1,360.9
Enterprise Value	—	—	—	—	16,781.4
Net Debt (memo)	560.4	310.2	1,112.1	1,164.5	1,164.5
EV per Share	—	—	—	—	853.80

Total Capital	5,006.3	5,248.7	6,385.1	7,029.8	7,029.8
Total Debt/Total Capital	12.70	8.20	18.72	19.36	19.36
Total Debt/EV	—	—	—	—	0.08

EV/Sales	—	—	—	—	2.16
EV/EBITDA	—	—	—	—	14.36
EV/EBIT	—	—	—	—	20.30
EV/Free Cash Flow	—	—	—	—	48.21
Reference Items — Trailing FY Values
Sales	5,652.6	6,228.6	6,672.1	7,344.9	7,784.0
EBITDA	708.4	933.4	1,008.2	1,118.5	1,169.0
EBIT	432.9	660.7	729.7	799.9	826.5
Operating Cash Flow	723.9	803.2	88.0	782.7	—
Free Cash Flow	280.5	475.7	-475.7	348.1	348.1
FCFF (free cash flow to the firm)	278.9	474.5	-489.6	345.2	—
Capital Expenditure	443.4	327.5	563.6	434.6	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.